MedTrace Logo

Effect of Cis-9-cetylmyristoleate in Sub-healthy Subjects Presenting With Knee Joint Pain

NCT02800759 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2016-06-15

No results posted yet for this study

Summary

Cis-9-cetylmyristoleate (CMO) is a naturally occurring fatty acid complex (FAC). Nutraceuticals containing CMO are used to improve knee pain despite the lack of placebo-controlled studies in humans. The aim of the double-blind controlled clinical trial is to explore the minimal effective dose of CMO for relieving knee joint pain.

Conditions

  • Knee Pain Intermittent

Interventions

DIETARY_SUPPLEMENT

JOINTRUS®

100% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate

DIETARY_SUPPLEMENT

80% dose of JOINTRUS®

80% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate

DIETARY_SUPPLEMENT

62.4% dose of JOINTRUS®

62.4% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate

DIETARY_SUPPLEMENT

Starch 100%

0% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate

Sponsors & Collaborators

  • Seoul National University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-07-31
Completion
2014-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02800759 on ClinicalTrials.gov